Evidence-based management strategies for endocrine complications after pituitary adenoma surgery

Abstract

This study aims to provide a clinical reference for the management of endocrine complications in pituitary tumor patients by synthesizing recent evidence for domestic and international management strategies. Based on the PIPOST (Population, Intervention, Professional, Outcome, Setting, and Type of Evidence) framework, evidence-based medicine targets were determined. Electronic decision support systems, guideline websites, and databases were searched to identify the best evidence on postoperative endocrine complications in pituitary tumors. The PICO (Patient, Intervention, Comparison, Outcome) principle was used to construct the search strategy, and the studies from the past 10 years (July 2013 to July 2023) were included. A total of 11 articles were included, including four guidelines, two expert consensus statements, one systematic review, one best practice article, and three randomized controlled trials. We obtained evidence on five aspects (endocrine assessment, secondary adrenal insufficiency management, water metabolism disorder management, special population management, and follow-up management) with a total of 30 pieces of evidence. Clinical healthcare professionals should focus on the care and follow-up of patients with postoperative complications, such as adrenal insufficiency, temporary or permanent diabetes insipidus, and hyponatremia. Future research should involve large sample sizes, long-term follow-ups, and multicenter studies to further clarify the protocols for fluid restriction, diet, and hormone use.

Keywords

complication management / endocrine / evidence-based medicine / pituitary adenoma

References

[1] Jane Jr. JA, Thapar K, Kaptain GJ, Maartens N, Laws Jr. ER. Pituitary surgery: transsphenoidal approach. Neurosurgery. 2002; 51(2): 435-444,

[2] Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011; 96(4): 894-904.

[3] Agam MS, Wedemeyer MA, Wrobel B, Weiss MH, Carmichael JD, Zada G. Complications associated with microscopic and endoscopic transsphenoidal pituitary surgery: experience of 1153 consecutive cases treated at a single tertiary care pituitary center. J Neurosurg. 2019; 130: 1576-1583.

[4] Nemergut EC, Dumont AS, Barry UT, Laws ER. Perioperative management of patients undergoing transsphenoidal pituitary surgery. Anesth Analg. 2005; 101(4): 1170-1181.

[5] de Vries F, Lobatto DJ, Verstegen MJT, van Furth WR, Pereira AM, Biermasz NR. Postoperative diabetes insipidus: how to define and grade this complication? Pituitary. Apr 2021; 24(2): 284-291.

[6] Deaver KE, Catel CP, Lillehei KO, Wierman ME, Kerr JM. Strategies to reduce readmissions for hyponatremia after transsphenoidal surgery for pituitary adenomas. Endocrine. 2018; 62(2): 333-339.

[7] Bohl MA, Ahmad S, Jahnke H, et al. Delayed hyponatremia is the most common cause of 30-day unplanned readmission after transsphenoidal surgery for pituitary tumors. Neurosurgery. 2016; 78(1): 84-90.

[8] Kristof RA, Rother M, Neuloh G, Klingmüller D. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study. J Neurosurg. 2009; 111(3): 555-562.

[9] Krogh J, Kistorp CN, Jafar-Mohammadi B, Pal A, Cudlip S, Grossman A. Transsphenoidal surgery for pituitary tumours: frequency and predictors of delayed hyponatraemia and their relationship to early readmission. Eur J Endocrinol. 2018; 178(3): 247-253.

[10] Zada G, Liu CY, Fishback D, Singer PA, Weiss MH. Recognition and management of delayed hyponatremia following transsphenoidal pituitary surgery. J Neurosurg. 2007; 106(1): 66-71.

[11] Hussain NS, Piper M, Ludlam WG, Ludlam WH, Fuller CJ, Mayberg MR. Delayed postoperative hyponatremia after transsphenoidal surgery: prevalence and associated factors. J Neurosurg. 2013; 119(6): 1453-1460.

[12] Burke WT, Cote DJ, Iuliano SI, Zaidi HA, Laws ER. A practical method for prevention of readmission for symptomatic hyponatremia following transsphenoidal surgery. Pituitary. 2018; 21(1): 25-31.

[13] Bohl MA, Ahmad S, White WL, Little AS. Implementation of a postoperative outpatient care pathway for delayed hyponatremia following transsphenoidal surgery. Neurosurgery. 2018; 82(1): 110-117.

[14] Hoffmann-Eßer W, Siering U, Neugebauer EAM, Brockhaus AC, Lampert U, Eikermann M. Guideline appraisal with AGREE II: systematic review of the current evidence on how users handle the 2 overall assessments. PLoS One. 2017; 12(3):e0174831.

[15] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4008.

[16] Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898.

[17] Deutschbein T, Jaursch-Hancke C, Knappe UJ, et al. First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors. Exp Clin Endocrinol Diabetes. 2021; 129(3): 250-264.

[18] Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab. 2016; 101(11): 3888-3921.

[19] Lamas C, del Pozo C, Villabona C. Guía clínica de manejo de la diabetes insípida y del síndrome de secreción inapropiada de hormona antidiurética en el postoperatorio de la cirugía hipofisaria. Endocrinol Nutr. 2014; 61(4): e15-e24.

[20] Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(8): 2807-2831.

[21] Tritos NA, Fazeli PK, McCormack A, et al. Pituitary Society Delphi Survey: an international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary. 2022; 25(1): 64-73.

[22] Chinese Pituitary Adenoma Collaborative Group. Expert consensus on surgical treatment of pituitary adenomas in China. Chin Med J. 2015; 95(5): 324-329.

[23] Yu S, Taghvaei M, Reyes M, et al. Delayed symptomatic hyponatremia in transsphenoidal surgery: systematic review and meta-analysis of its incidence and prevention with water restriction. Clin Neurol Neurosurg. 2022; 214:107166.

[24] Prete A, Corsello SM, Salvatori R. Current best practice in the management of patients after pituitary surgery. Ther Adv Endocrinol Metab. Mar 2017; 8(3): 33-48.

[25] Guo X, Zhang D, Pang H, et al. Safety of withholding perioperative hydrocortisone for patients with pituitary adenomas with an intact hypothalamus–pituitary–adrenal axis: a randomized clinical trial. JAMA Network Open. 2022; 5(11):e2242221.

[26] Koundal H, Dhandapani M, Thakur P, et al. Effectiveness of dietary diabetes insipidus bundle on the severity of postoperative fluid imbalance in pituitary region tumours: a randomized controlled trial. J Adv Nurs. 2021; 77(9): 3911-3920.

[27] Sterl K, Thompson B, Goss CW, et al. Withholding perioperative steroids in patients undergoing transsphenoidal resection for pituitary disease: randomized prospective clinical trial to assess safety. Neurosurgery. 2019; 85(2): E226-E232.

[28] Yedinak C, Hameed N, Gassner M, Brzana J, McCartney S, Fleseriu M. Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study. Pituitary. 2015; 18(5): 701-709.

[29] Jahangiri A, Wagner J, Han SW, et al. Rate and time course of improvement in endocrine function after more than 1000 pituitary operations. Neurosurgery. 2014; 61(suppl 1): 163-166.

[30] Woodmansee WW, Carmichael J, Kelly D, Katznelson L. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: postoperative management following pituitary surgery. Endocr Pract. 2015; 21(7): 832-838.

[31] Fang F, Zhang Y, Tang J, et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern Med. 2019; 179(2): 213-223.

[32] McLaughlin N, Cohan P, Barnett P, Eisenberg A, Chaloner C, Kelly DF. Early morning cortisol levels as predictors of short-term and long-term adrenal function after endonasal transsphenoidal surgery for pituitary adenomas and Rathke's cleft cysts. World Neurosurg. 2013; 80(5): 569-575.

[33] Manuylova E, Calvi LM, Vates GE, Hastings C, Shafiq I. Morning serum cortisol level after transsphenoidal surgery for pituitary adenoma predicts hypothalamic-pituitary-adrenal function despite intraoperative dexamethasone use. Endocr Pract. 2015; 21(8): 897-902.

[34] Hannon MJ, Finucane FM, Sherlock M, Agha A, Thompson CJ. Disorders of water homeostasis in neurosurgical patients. J Clin Endocrinol Metab. 2012; 97(5): 1423-1433.

[35] Adams JR, Blevins Jr. LS, Allen GS, Verity DK, Devin JK. Disorders of water metabolism following transsphenoidal pituitary surgery: a single institution's experience. Pituitary. 2006; 9(2): 93-99.

[36] Barber S, Liebelt B, Baskin D. Incidence, etiology and outcomes of hyponatremia after transsphenoidal surgery: experience with 344 consecutive patients at a single tertiary center. J Clin Med. 2014; 3(4): 1199-1219.

[37] Alwis US, Haddad R, Monaghan TF, et al. Impact of food and drinks on urine production: a systematic review. Int J Clin Pract. 2020; 74(9):e13539.

[38] Prevedello DM, Pouratian N, Sherman J, et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging: clinical article. J Neurosurg. 2008; 109(4): 751-759.

[39] Mukherjee A, Murray RD, Teasdale GM, Shalet SM. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status. Clin Endocrinol. 2004; 60(4): 476-483.

[40] Shin MS, Yu JH, Choi JH, et al. Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma. Neurosurgery. 2013; 73(3): 473-479,

[41] Katznelson L, Laws Jr. ER, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11): 3933-3951.

[42] Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014; 10(4): 243-248.

RIGHTS & PERMISSIONS

2024 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University and Wiley-VCH GmbH.